MedCity News July 27, 2021
Frank Vinluan

Amgen is paying $900 million up front to acquire Teneobio, a biotech with technology for discovering and developing antibody drugs. Though Amgen already has its own antibody platform, the company says Teneobio’s technology and drug assets will complement its own.

Amgen already has an antibody platform, technology that has yielded drugs that have gone on to secure FDA approval as well as more therapeutic candidates still in the pipeline. But in Teneobio, Amgen sees an attractive alternative technology for antibody drug discovery and development, and the pharmaceutical giant has agreed to pay $900 million to acquire the entire company.

The cash sum is an upfront payment. According to deal terms announced after the market close Tuesday, Teneobio shareholders could earn...

Today's Sponsors

Transcarent
SalesSparx
Canton & Company

Today's Sponsors

Oscar
Curation Health

Today's Sponsor

TripleTree

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Adrian Cheng Moves Deeper Into Healthcare Industry With Artisan Merger Of Prenetics At $1.2 Bln Valuation
Northwell Health inks deal with Walgreens to provide telehealth, primary care in N.Y. retail stores
Care Hospice Acquires Hospice of Chattanooga, Alleo Health System
symplr to Acquire Halo Health
Hillrom VP of connected care talks Baxter's $10.5B buy, digital health